Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder

Libyan Journal of Medicine

Volumn 7, Issue 1, 2012, Pages

  El Gehani, Khaled ^a   Al Kikhia, Lamia ^a   Emaetig, Fatma ^a   Syrjänen, Kari ^b   Al Fituri, Omran ^a   Elzagheid, Adam ^a  

^a UNIVERSITY OF BENGHAZI   (Libyan Arab Jamahiriya)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bladder cancer; Human epidermal growth factor receptor 2; Immunohistochemistry; Over expression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGE; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SEX RATIO; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA; TUMOR DIFFERENTIATION;

EID: 84859141620     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v7i0.14694     Document Type: Article

References (48)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27: 289-93.
2. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008; 218: 12-20.
3. Canoglu A, Gogus C, Beduk Y, Orhan D, Tulunay O, Baltaci S. Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis. Int Urol Nephrol. 2004; 36: 401-5.
4. Von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23: 4602-8.
5. Duncan W, Quilty PM. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. Radiother Oncol. 1986; 7: 299-310.
6. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-75.
7. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, et al. Distinctive expression pattern of Erb-b famil receptors signify an aggressive variant of bladder cancer. J Urol. 2008; 179: 353-8.
8. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA, Bartlett JM. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 2003; 89: 1305-9.
9. Reznikoff CA, Sarkar S, Knut PJ, Burger MS, Newton MA. Genetic alterations and biological pathways in Human bladder cancer pathogenesis. Urol Oncol. 2000; 5: 191-203.
10. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19: 3159-67.
11. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61(Suppl. 2): 1-13.
12. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992; 89: 4285-9.
13. Berger MS, Greenfield C, Gullick WJ, Haley J, Downward J, Neal DE, et al. Evaluation of epidermal growth factor receptors in bladder tumors. Br J Cancer. 1987; 56: 533-7.
14. Mitra AP, Lin H, Datar RH, Cote RJ. Molecular biology of bladder cancer: prognostic and clinical implications. Clin Genitourin Cancer. 2006; 5: 67-77.
15. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001; 7: 2440-7.
16. Elzagheid A, Kuopio T, Ilmen M, Collan Y. Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance. Histopathology. 2002; 41: 127-33.
17. Lipponen P, Collan Y. Simple quantitation of immunohistochemical staining positivity in microscopy. Acta Stereol. 1992; 11: 125-32.
18. Zhau HE, Zhang X, von Eschenbach AC, Scorsone K, Babaian RJ, Ro JY, et al. Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer. Mol Carcinog. 1990; 3: 254-7.
19. Tetu B, Fradet Y, Allard P, Vellleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol. 1996; 155: 1784-8.
20. Lee SE, Chow NH, Chi YC, Tzai TS, Yang WH, Lin SN. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer. Anticancer Res. 1994; 14: 1317-24.
21. Mellon JK, Lunec J, Wright C, Home CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol. 1996; 155: 321-6.
22. Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol. 1994; 101: 166-76.
23. Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, et al. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract. 1997; 193: 767-75.
24. Lipponen P, Eskelinen M, Syrjanen S, Tervahauta A, Syrjanen K. Use of immunohistochemically demonstrated c-erb B-2 oncoprotein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol. 1991; 20: 238-42.
25. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R, Cooke T. C-erbB-2 gene amplification: a molecular marker in recurrent bladder tumors? Cancer Res. 1995; 55: 2422-30.
26. Lonn U, Lonn S, Friberg S, Nilsson B, Silfersward C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res. 1995; 1: 1189-94.
27. Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. Cancer. 1998; 82: 715-23.
28. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. c- erbB-2 oncoprotein expression in primary human tumors. Cancer. 1990; 65: 88-92.
29. Matsubara H, Yamada Y, Naruse K, Nakamura K, Aoki S, Taki T, et al. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: Comparative study of immunohistochemistry and fluorescent in situ hybridization. Oncol Rep. 2008; 19: 57-63.
30. Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom PU. HER-2, a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol. 2002; 41: 282-8.
31. Gardmark T, Wester K, De la Torre M, Carlsson J, Malmström PU. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 2005; 95: 982-6.
32. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010; 106: 1216-22.
33. Janane A, Hajji F, Ismail TO, Elondo JC, Ghadouane M, Ameur A, et al. Evaluation of HER2 protein overexpression in non-muscle invasive bladder cancer with emphasis on tumour grade and recurrence. Actas Urol Esp. 2011; 35: 189-94.
34. Naik DS, Sharma S, Ray A, Hedau S. Epidermal growth factor receptor expression in urinary bladder cancer. Indian J Urol. 2011; 27: 208-14.
35. Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis AO, et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J BUON. 2009; 14: 457-62.
36. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol. 2008; 40: 321-7.
37. Gorgoulis VG, Barbatis C, Poulias I, Karameris AM. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol. 1995; 8: 758-64.
38. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F. P53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol. 1993; 423: 329-34.
39. Moriyama M, Akiyama T, Yamamoto T, et al. Expression of C-ERBB-2 gene product in urinary bladder cancer. J Urol. 1991; 145: 423-7.
40. Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002; 95: 1009-15.
41. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002; 102: 514-8.
42. Alexa A, Baderca F, Zahoi DE, Lighezan R, Izvernariu D, Raica M. Clinical significance of Her2/neu overexpression in urothelial carcinomas. Rom J Morphol Embryol. 2010; 51: 277-82.
43. Tommasi S, Ditonno P, Sisto M, Paradiso A, Gentile A, Ricco R, et al. HER-2/neu in bladder carcinoma. Int J Oncol. 1996; 8: 957-61.
44. Badr KM, Nolen JD, Derose PB, Cohen C. Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2/neu, and proliferation (MIB-1). Hum Pathol. 2004; 35: 184-9.
45. Eissa S, Ali HS, Al Tonsi AH, Zaglol A, El Ahmady O. HER2/neu expression in bladder cancer: relationship to cell cycle kinetics. Clin Biochem. 2005; 38: 142-8.
46. Fornaro L, Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, et al. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011; 8: 369-83.
47. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. Cancer Treat Rev. 2010; 36(Suppl. 3): 11-5.
48. Gravalos C, Gomez-Martin C, Rivera F, Ales I, Queralt B, Marquez A, et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol. 2011; 13: 179-84.